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Background: The concepts of medication adherence and Treatment satisfactions are commonly used in clinical
research for assessing pharmaceutical care and improving treatment outcomes. Generally, one would expect a
positive relationship between the two concepts. The objectives of this study were to investigate the factors
associated with adherence to antihypertensive therapy among hypertensive patients and to assess the relationship
between antihypertensive medication adherence and treatment satisfaction.
Methods: A cross-sectional study was conducted, adopting the Morisky eight-item Medication Adherence Scale (MMAS)
for the assessment of medication adherence and using the Treatment Satisfaction Questionnaire for Medication (TSQM
1.4) for the assessment of treatment satisfaction. Descriptive and comparative statistics were used to describe socio-
demographic and disease-related characteristics of the patients. All analyses were performed using SPSS v 15.0.
Results: Four hundred and ten hypertensive patients were enrolled in the study. The mean age of participants was
58.38 ± 10.65 years; 52% were female and 36.8% had low antihypertensive medication adherence. There was a significant
difference in the mean scores in the Effectiveness (p < 0.001), Convenience (p < 0.001), and Global Satisfaction (p < 0.001)
domains, but not in the Side Effects (p = 0.466) domain among patients with different levels of adherence. After
adjustment for covariates using multiple linear regression, global treatment satisfaction was still statistically significantly
(p = 0.001) associated with medication adherence.
Conclusions: Low treatment satisfaction may be an important barrier for achieving high rates of adherence to treatment.
These study findings could be helpful in clinical practice, mainly in the early treatment of hypertensive patients, at a point
where improving treatment satisfaction is still possible.
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Hypertension is a condition with a tremendous economic
and public health impact which contributes to disability,
health care costs and mortality [1]. Although the manage-
ment and control of hypertension reduces morbidity and
mortality, the percentage of patients with controlled
hypertension has been reported to vary between 5.4% and* Correspondence: saedzyoud@yahoo.com
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reproduction in any medium, provided the or58% worldwide [2]. One factor contributing to less than
ideal blood pressure control is low adherence to treatment
[3,4]. Multiple factors that influence patient adherence to
prescribed therapies have been illustrated; these include
treatment satisfaction, high incidence of adverse effects of
blood pressure-lowering drugs, health care system issues,
quality of life, socio-demographics, lack of knowledge re-
garding hypertension, and treatment and clinical variables
[5-7]. Treatment satisfaction is believed to affect the pa-
tient’s health- related decision making [8]. The impact of
low treatment satisfaction on medication adherence is of
particular alarm in patients with chronic diseases. It hasLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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illness end up making medication-related decisions with-
out looking for medical advice, becoming “non-adherent”
to such an extent that they compromise the effectiveness
of treatment [8]. Therefore, health care providers need to
identify patients’ level of satisfaction with the medications
they are using. To evaluate this, measures for assessing
treatment satisfaction have been developed [9].
Despite the assessment of adherence, treatment satis-
faction, or both in many studies, only limited studies
have been performed to measure the relationship be-
tween adherence to drug treatment and treatment satis-
faction among hypertensive patients. Given the small
number of studies in which the association between
adherence and treatment satisfaction has been inves-
tigated [6,10,11], a review of the literature revealed no
studies on medication adherence and treatment sa-
tisfaction among patients with hypertension in the Arab
world. This is important given that culture and religion
might play a role in health-related issues; the objec-
tives of this study were to investigate the factors
associated with adherence to antihypertensive therapy
among hypertensive patients and to assess the rela-
tionship between antihypertensive medication adher-
ence and treatment satisfaction.
Methods
Study design, participants and setting
A cross-sectional study design was used to address the
research goals. The study was conducted in outpatients’
clinics at Al-Makhfyah primary health care clinic and at
Alwatani Hospital, Nablus district in Palestine. These are
the largest public institutes in Nablus district. Being gene-
ralised in nature, they provide health care for all chronic
illnesses. Most patients in Palestine consult within the
government health care system [12].
In two population-based cross-sectional studies carried
out previously, the rate of hypertension in two commu-
nities from the West Bank ranged from 21.5% to 25.4%
in adults aged 30–65 years [13]. Therefore, a prevalence-
based sample of 385 hypertensive patients was selected
for this study [14]. In order to minimise erroneous re-
sults and increase the study reliability, the target sample
size was increased to 410 patients. Therefore, a conveni-
ence sample of 410 hypertension outpatients was identi-
fied between July 2012 and October 2012.
The inclusion criteria were (1) patients diagnosed with
hypertension at least six months before recruitment into
the study, (2) patients treated for hypertension with anti-
hypertensive medications, (3) aged 18 years and over, (4)
able to recognise their medications from the total medi-
cations that they took daily, and (5) patients who were
willing to participate and who had given verbal consent
to participate in the study.Ethical approval
This study received approval from the Palestinian Minis-
try of Health and Institutional Review Board (IRB) at
An-Najah National University. Verbal consent was also
obtained from the patients prior to the commencement
of the study.The IRB considered waiving the require-
ment to obtain verbal consent for our protocols that
were clearly below minimal risk and the research did not
involve any therapeutic intervention.
Data collection
On the day of the assessment, data were collected using
a set of questionnaires. Four main variables were used:
(1) socio-demographic data, (2) clinical hypertension re-
lated data, (3) medication adherence profile of hyperten-
sive patients; and (4) treatment satisfaction profile of
hypertensive patients.
Assessment of medication adherence
The Morisky scale, also known as the Morisky Medication
Adherence Scale (MMAS), was used for the assessment of
medication adherence [3,15]. The English version of the
MMAS was translated into Arabic and was approved by
Professor Morisky through e-mail communications [16].
The Arabic version of the MMAS is an eight-item ques-
tionnaire with seven yes/no questions and one question
answered on a five-point Likert scale. According to the
scoring system of the MMAS, scores can range from zero
to eight, with MMAS scores of <6, 6 to <8 and 8 reflecting
low, medium and high adherence, respectively [3,17]. The
internal consistency and validity of the questionnaire was
ensured (Cronbach’s alpha value was 0.723 for the instru-
ment used in our study).
Assessment of treatment satisfaction
Treatment satisfaction was tested using the Arabic version
of the Treatment Satisfaction Questionnaire for Medication
(TSQM 1.4), which the researchers obtained from Quintiles
Strategic Research Services. The TSQM 1.4 is a 14-item
psychometrically robust and validated instrument compris-
ing four domains [9]. Effectiveness (questions 1–3), Side Ef-
fects (questions 4–8), Convenience (questions 9–11), and
Global Satisfaction (questions 12–14). The TSQM 1.4 do-
main scores were calculated as recommended by the in-
strument’s authors and described in detail elsewhere [6,18].
TSQM 1.4 domain scores range from 0 to 100, with higher
scores representing higher satisfaction in that domain. The
“Global Satisfaction” scale of the TSQM is used to assess
the overall level of satisfaction or dissatisfaction with medi-
cations that patients are taking. Patients’ global rating of
dissatisfaction with treatment is the strongest predictor of
non-adherence and non-persistence with medication use,
thereby affecting the clinical effectiveness and efficiency
of medical care. Patients who recognize their medication to
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as having more negative than positive characteristics are
less likely taking their medications as prescribed. This in
turn can impact the effectiveness of treatment and may
result in service inefficiencies associated with treatment
failure. TSQM provides a unique opportunity to compare
various medications used to treat a particular illness on the
three primary dimensions of treatment satisfaction (Effec-
tiveness, Side Effects, Convenience), as well as patients’
overall rating of Global Satisfaction based on the relative
importance of these primary dimensions to patients. Rou-
tine assessment of patients’ level of treatment satisfaction
provides a way for health care providers to screen in-
dividuals whose current medication experiences may
increase the risk of poor medication adherence and per-
sistence. If collected from many patients, such informa-
tion could promote a deeper consideration of patients’
perspectives when evaluating drawbacks of various
treatment strategies [6,9,18]. The internal consistency
and validity of the questionnaire was ensured for the
instrument used in our study namely Effectiveness (3
items, Cronbach’s Alpha =0.92), Side effects (4 items,
Cronbach’s Alpha =0.97), Convenience (3 items, Cron-
bach’s Alpha =0.86), and Global Satisfaction scale (3
items, Cronbach’s Alpha =0.89).
Data collection procedure
Data collection was carried out by face-to-face inter-
views with the patients by trained senior Pharm D stu-
dents. The data collection was pre-tested in through a
pilot study of 10 patients who were not included in the
final analysis to check for the understandability and lan-
guage clarity of questions, and all valid comments were
taken into consideration by the principal researchers in
the main survey, and the modified version was reviewed
by experts to ensure content and construct validity. A
total of 410 patients were eligible and included in the
final analysis with a response rate of 96.4%. Regular eval-
uations took place throughout the abstraction period to
identify any problems in data collection, interpretation
of definitions, and application of study criteria. Before
commencing data analysis, an extensive series of checks
were performed for data consistency, proper sequences
of data, and an evaluation of missing or incomplete data.
Statistical analysis
Data were entered and analysed using the Statistical
Package for Social Sciences (SPSS; SPSS Inc., Chicago, IL,
USA) program version 15. Spearman’s correlation coef-
ficient was used to identify the relationship between the
MMAS score and TSQM scores. Multiple linear regres-
sion analysis was used to evaluate the correlation of the
factors with medication adherence. Internal consistency
was assessed using Cronbach’s alpha. Descriptive andcomparative statistics were used to describe socio-
demographic and disease-related characteristics of the pa-
tients. The internal consistency and validity of the MMAS
and TSQM were ensured. Variables were tested for nor-
mality using the Kolmogorov–Smirnov test. Intergroup
differences in MMAS scores were assessed for statistical
significance using either Mann–Whitney or Kruskal–
Wallis test for numerical data, as appropriate. Furthermore,
differences in means among MMAS levels and TSQM
scores were tested using one-way ANOVA with Tukey’s
post hoc test. The significance level was set at P < 0.05.
Results
Demographic characteristics
Table 1 describes the socio-demographic characteristics of
the study participants. Two hundred and thirteen (52%)
patients of the study population were female. The mean
age of the study population was 58.38 ± 10.65 years (range:
30–90 years). The majority (46.2%) of patients in the study
population were obese. A total of 245 patients (59.8%) had
low income, 194 (47.3%) had village residency and the ma-
jority of patients had a primary level of education. The
mean duration of hypertension was 7.34 years (SD = 5.90).
The median number of total medications per day was 4.0
(interquartile range: 3.0–6.0). The majority of patients
(86.8%) were on combination antihypertensive medicines.
Medication adherence
The median MMAS score was 7.0, (interquartile range:
4.8–8.0). Using published MMAS-8 thresholds [3], 36.8%
of participants had low, 26.8% had medium and 36.2%
had high antihypertensive medication adherence. As
shown in Table 1, a significant difference in MMAS score
was found between participant groups according to age,
marital status, educational level, total number of chronic
diseases, and total number of medications (Kruskal–
Wallis test; p < 0.05), as well as gender and therapy type
(Mann–Whitney test, p < 0.05). Patients aged over 68 years
had a lower median MMAS score than those age groups
of less than 68 years. Furthermore, female gender was as-
sociated with a higher MMAS score. The study found that
MMAS score increased as the educational level of patients
increased. Also, it was found that MMAS score decreased
as the total number of chronic diseases and total number
of medications increased. A significantly lower MMAS
score was seen in participants receiving combination ther-
apy as hypertension treatment.
Treatment satisfaction and its relationship between
medication adherence
TSQM score was measured as good. The average satisfac-
tion scores in the Effectiveness, Side Effects, Convenience,
and Global Satisfaction domains were 62.1 ± 20.5, 86.0 ±
26.5, 67.2 ± 14.0, and 72.1 ± 23.1, respectively. Furthermore,
Table 1 Socio-demographic and disease-related character-
istics of the study patients with differences in adherence
total scores (N = 410)
Variable
Frequency (%) Morisky score
p-valueMedian
N = 410 [interquartile range]
Age category
28-37 13 (3.2) 8.0 [5.3-8.0] 0.042a
38-47 39 (9.5) 7.0 [4.8-8.0]
48-57 149 (36.3) 7.0 [4.8-8.0]
58-67 119 (29) 7.0 [5.0-8.0]
≥68 90 (22) 5.8 [4.7-7.8]
Gender
Male 197 (48.0) 6.8 [4.8-8.0] 0.048b
Female 213 (52.0) 7.0 [5.5-8.0]
BMI
Normal 35 (8.5) 7.0 [5.3-8.0] 0.231a
Overweight 183 (44.6) 7.0 [4.8-8.0]
Obese 192 (46.2 6.8 [4.8-8.0]
Residency
Village 194 (47.3) 7.0 [4.8-8.0] 0.626a
City 166 (40.5) 6.8 [4.8-8.0]
Palestinian
refugee camps
50 (12.2) 7.6 [5.0-8.0]
Occupation
Employed 156 (38.0) 7.0 [4.8-8.0] 0.089a
Unemployed 63 (15.4) 6.0 [4.8-8.0]
Housewife 191 (46.6) 7.0 [5.0-8.0]
Marital status
Single 13 (3.2) 8.0 [6.5-8.0] 0.012a
Married 346 (84.4) 7.0 [4.8-8.0]
Divorced 12 (2.9) 5.1 [3.0-6.8]
Widowed 39 (9.5) 6.8 [4.5-8.0]
Income (NISc)
Less than 2000 245 (59.8) 7.0 [4.8-8.0] 0.101a
2000-5000 150 (36.6) 7.0 [4.8-8.0]
More than 5000 15 (3.7) 6.5 [4.5-8.0]
Education
No formal 40 (9.8) 6.8 [4.5-8.0] 0.009a
Primary 149 (36.3) 7.0 [5.0-8.0]
Secondary 112 (27.3) 6.5 [4.8-8.0]
University 109 (26.9) 7.8 [5.8-8.0]
Duration of the disease
< 1 year 4 (1.0) 7.3 [3.7-7.9] 0.451a
1-3 years 120 (29.3) 7.0 [4.8-8.0]
4-5 years 93 (22.7) 7.0 [5.0-8.0]
≥ 5 years 193 (47.1) 6.8 [4.8-8.0]
Table 1 Socio-demographic and disease-related character-
istics of the study patients with differences in adherence
total scores (N = 410) (Continued)
Therapy type
Mono therapy 54 (13.2) 8.0 [5.5-8.0] 0.004b
Multi therapy 356 (86.8) 6.8 [4.8-8.0]
Total number of
chronic diseases
0 151 (36.8) 7.0 [5.0-8.0] 0.016a
1 159(38.8) 6.8 [4.8-8.0]
2 79 (19.3) 7.0 [5.5-8.0]
≥4 21 (5.1) 4.8 [3.6-7.4]
Total number of
medications
1-3 166(40.5) 7.3 [5.0-8.0] 0.006a
4-6 172(42.0) 6.8 [4.8-8.0]
≥7 72(17.6) 5.9 [4.7-7.8]
Abbreviations: BMI Body mass index; NIS New Israeli Shekel.
aStatistical significance of differences calculated with the Kruskal-Wallis test.
bStatistical significance of differences calculated with the Mann–Whitney U test.
c1 Israeli New Sheqel equals 0.27 US Dollar.
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50–77), the median Side Effects score was 100, (interquar-
tile range: 98–100), the median Convenience score was 66,
(interquartile range: 61–78), and the median Global Satis-
faction score was 83, (interquartile range: 58–92). There
were a significantly strong positive correlation between
Global Satisfaction score and Effectiveness domain (r =
0.79; p < 0.001), Side Effects domain (r= 0.24; p < 0.001),
and Effectiveness (r = 0.59; p < 0.001).
There was a significant difference in the mean scores in
the Effectiveness (p <0.001), Convenience (p < 0.001), and
Global Satisfaction (p <0.001) domains, but not in the
Side Effects (p = 0.466) domain among patients with dif-
ferent levels of adherence. Patients with a high adherence
rate had the highest global treatment satisfaction scores
compared with those with a low or medium adherence
rate. The Spearman’s rank order correlation coefficient be-
tween total adherence and overall TSQM score indicated
a significant positive correlation (r = 0.337; p < 0.001).
Multiple linear regression analysis
The previous analysis did not take into account the effect
of confounding factors, which may affect the relationship
between these factors and medication adherence in pa-
tients with hypertension. From the univariate analysis,
age, gender, marital status, educational level, therapy type,
number of chronic diseases and amount of medication
were found to be statistically significant P < 0.05 (Table 1).
As recommended by Tabachnick and Fidell [19], the inde-
pendent variables should be strongly related to the de-
pendent variable but they should not strongly related to
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correlations between the domains of TSQM, highly inter-
correlated variables were excluded. Therefore, the general
global treatment satisfaction domain was included in the
multiple linear regression model, while other domains were
excluded (Table 2). After adjusting the covariates using
multiple regression, global treatment satisfaction was still
statistically significantly (p = 0.001) associated with medica-
tion adherence (R = 0.373; adjusted R2 = 0.122; F = 8.107;
df = 8; p < 0.001). No multicollinearity was found among
the independent variables (the minimum tolerance was
1.06 and the maximum variance inflation factor (VIF) for
multicollinearity was 2.96). Table 2 shows the contribution
of each independent variable to adherence. Beta values are
usually used to achieve this purpose, with the highest
absolute value indicating the strongest contribution to
adherence. In our model the largest beta coefficient was
0.30, which was for global treatment satisfaction variable
(Table 2). This means that global treatment satisfaction
made the strongest unique contribution to explaining
variations in medication adherence. Thus, higher scores in
TSQM predicted higher scores in MMAS.
Discussion
To the best of our knowledge, no studies of the determi-
nants of adherence and treatment satisfaction among pa-
tients with hypertension in Palestine have been carried out
previously. Although limited studies have reported medi-
cation adherence among Arab populations suffering from
different diseases, there is a lack of data concerning medi-
cation adherence and treatment satisfaction solely among
hypertensive patients. This is therefore the first attempt to
determine the relationship between medication adher-
ence and treatment satisfaction in Palestine and Arab
hypertensive patients. An improved understanding of
the determinants associated with medication adherence
and treatment satisfaction has become an important
outcome in management strategies for hypertension
[6,18]. Such understanding will help predicting hyper-
tensive patient’s life and perceptions of illness. There-







Number of chronic diseases −0.04
Number of medications −0.01
Global treatment satisfaction 0.29
Abbreviations: β Beta standardized linear regression coefficient; 95% CI 95% confidehealth care settings was to assess the relationship be-
tween medication adherence and treatment satisfaction
in hypertensive patients. Determining patient adherence
to antihypertensive medications in outpatient settings is
an important first step for physicians and other health
care providers in understanding the effectiveness of or
satisfaction to the treatments they prescribe, identifying
barriers to treatment, and improving blood-pressure
control [20]. It is important for health care providers to
consider low treatment satisfaction or low medication
adherence as a factor contributing to poor blood pres-
sure control to actively engage patients in the selection
of strategies to improve adherence [9,18,21]. The ability
to identify indicators of low medication adherence is
crucial for both improving clinical care and determining
targets of intervention for the prevention of complica-
tions and treatment of hypertension.
A review of the literature revealed that adherence to
treatment of hypertension is influenced by a number of
factors [3,22-24]. Medication adherence rates have been
shown to be related with age, gender, and race [25,26].
Other factors are modifiable which reported negatively im-
pact adherence to prescribed medications include depres-
sion [27], lack of knowledge regarding hypertension and its
treatment [28], complexity of medication regimen [29], side
effects of medication [30], patient satisfaction [3], and poor
quality of life [7]. In our study, we identified one modifiable
variable in the multiple regression model that predict medi-
cation adherence. Some of the interesting findings in the
model indicated that treatment satisfaction was signifi-
cantly associated with medication adherence. This implies
the need for effective communication between the phys-
ician or pharmacist and patients to improve understanding
regarding hypertension and its treatment.
Treatment satisfaction may be associated with medication
adherence for several reasons, including patients’ attitudes
or beliefs towards taking antihypertensive medications [31].
Morisky et al. [3] and Bharmal et al. [6] stated that the exact
mechanism through which treatment satisfaction is as-
sociated with medication adherence is unknown; however,
low treatment satisfaction appears to be associated witheen factors and medication adherence









nce interval for B unstandardized linear coefficients.
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patient’s ability to manage their chronic illnesses and other
health problems. Previous studies performed among hyper-
tensive patients have linked treatment satisfaction to numer-
ous factors, which are recognised to be precursors to
medication adherence. These include patients’ beliefs, their
perceived level of competence, knowledge and attitudes
about disease treatment, and their overall attitude to life
[3,6,10,11]. Further research is needed to understand the real
mechanisms through which treatment satisfaction is associ-
ated with adherence to antihypertensive medications.
Our study is the first one to assess adherence and sat-
isfaction among Arab patients with hypertension using
validated tools; however, our study has a few limitations.
Firstly, the major limitation of this study is its cross-
sectional design, which precludes causal relationships to
be identified. Secondly, no account has been made of
hypertension severity, therefore, a more accurate meas-
ure may be needed to assess whether blood pressure is
well controlled or not. Finally, the participants were
drawn from one district and therefore, our findings
cannot be generalised to the entire country.
Conclusions
We conclude that participants with low treatment
satisfaction are more likely to have lower adherence to
antihypertensive medications. In conclusion, the results of
this study support the hypothesis that treatment satisfac-
tion is reliable indicators of adherence to antihypertensive
medications in patients presenting with hypertension in
Palestine. Thus, low treatment satisfaction may be an
important barrier to achieving high rates of adherence to
treatment. Patients should be educated about the advan-
tages of self-management of diseases, and the common
perception that drugs are inherently unsafe has to be
eliminated. Further research is also recommended in
order to identify appropriate and targeted interventions in
an effort to improve treatment satisfaction in patients
with hypertension.
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